The Russian Ministry of Health has registered the first national quadrivalent vaccine for the prevention of meningococcal infection, named "Mentra", according to what was announced by "Petrofax Pharm", the vaccine manufacturer.
Hot Topics
About half of Libyans drink contaminated water What is the scientific reason?
Mauritania's blue treasure is in danger Will the map of fish in the Atlantic be redrawn?
The Citrus Secret Everyone's Talking About: Burn More, Crave Less & Feel Great Naturally
A statement released by the company read: "Petrovaxpharm has received registration certification for the quadrivalent Mentera vaccine for the prevention of meningococcal infection. The registration of the vaccine opens new horizons for expanding the scope of preventive immunizations at the national level and protecting the lives and health of children from an infection that has mortality rates of up to 20%."
In 2025, the vaccine passed Phase III clinical trials in Russia, involving 18 medical centers. The results showed efficacy similar to the comparator vaccine, and even superiority in some indicators of immune response.
“Meningococcal infection remains one of the most dangerous vaccine-preventable infectious diseases,” said Yuri Lobzin, professor and member of the Russian Academy of Sciences. “The disease develops rapidly and can lead to the death of a child in just 24 hours, and more than 28% of survivors suffer severe consequences that can lead to disability. Nevertheless, we continue to observe an increase in infection rates, which makes prevention extremely important.”
The company added that Mentetra is intended for the prevention of meningococcal infection caused by serogroups A, C, W, and Y. It can be used to vaccinate children from the age of three months, as well as adults up to the age of 55.
According to medical instructions, the recommended vaccination schedule for children aged 3 to 5 months includes three doses, while children aged 6 to 23 months receive two doses. Children aged 2 years and older, as well as adults aged 18 to 55 years, receive one dose.
Meningococcal infection is a bacterial infection caused by Neisseria meningitidis. Its generalized forms are particularly dangerous, often developing rapidly. Those most at risk include young children, adolescents, the elderly, and people with weakened immune systems.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media
